TAILIN BIOTECH(SZ:300813) 仪器信息网·2025-10-27 09:07Financial Performance - The company's operating revenue for the reporting period was 67,363,245.41 yuan, a decrease of 21.84% compared to the same period last year [2] - The net profit attributable to shareholders was 1,180,325.54 yuan, down 75.06% year-on-year [2] - The basic earnings per share decreased by 75.00% to 0.01 yuan, while diluted earnings per share dropped by 100.00% to 0.00 yuan [2] - The total assets at the end of the reporting period were 934,063,765.94 yuan, a decrease of 2.69% from the previous year [2] Cash Flow Analysis - The net cash flow from operating activities was 14,859,155.99 yuan, an increase of 171.73% compared to the previous period [7] - The net cash flow from investing activities was 18,597,586.88 yuan, a decrease of 34.57% year-on-year [7] - The net cash flow from financing activities was -40,384,964.10 yuan, a significant decrease of 954.70% compared to the previous period [7] Shareholder Information - The total number of ordinary shareholders and the top ten shareholders' holdings were detailed, with the largest shareholder holding 18,402,400 shares [9] - The company has a significant relationship between major shareholders, indicating potential influence on corporate governance [9] Changes in Financial Indicators - The company experienced a 49.04% decrease in cash and cash equivalents due to investments in structured deposits and wealth management products [6] - The accounts receivable increased, leading to a 245.94% rise in credit impairment losses [7] - The company reported a 90.80% decrease in other non-current assets, primarily due to a reduction in equipment prepayments [6]